Aion Therapeutic Inc.

Aion Therapeutic Inc.

Aion Therapeutic Announces Proposed Non-Brokered Private Placement Offering of Units

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE U.S./TORONTO, July 4, 2023 - Aion Therapeutic Inc. (CSE: AION)Β ("Aion Therapeutic" or theΒ "Company")Β is pleased to announce that it plans to undertake a non-brokered private placement of up to 50,000,000 units ("Units") to raise gross proceeds of up to $500,000.00... Read More...

Aion Therapeutic Files Financials

Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").Management of... Read More...

Aion Therapeutic Provides Default Status Update

TORONTO, Sept. 14, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). On August 31, 2021, the Company anno... Read More...

Aion Therapeutic Provides Notice of Default

TORONTO, Aug. 31, 2021 - Aion Therapeutic Inc. (CSE: AION)Β ("Aion Therapeutic" or the "Company") announces that it anticipates being late in filing its audited annual financial statements (the "Annual Financial Statements") and related management discussion and analysis ("MD&A") for the year ended April 30, 2021, by the prescribed dea... Read More...

Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways

LONDON and TORONTO, May 18, 2021 -Β Apollon Formularies plc (AQSE: APOL)Β ("Apollon" or theΒ "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, andΒ Aion Therapeutic Inc. (CSE: AION)Β ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange,Β are pleased ... Read More...

Aion Therapeutic Amends Convertible Debentures

Toronto, Ontario--(Newsfile Corp. - October 30, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company has entered into a convertible debenture extension and amendment agreement (the "Amending Agreement") dated October 29, 2020 with Quinsam Capital Corporation (the "Lender"). The A... Read More...

Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer

Dr. Fritsche has also been appointed Chief Science Officer of AI Pharma, a wholly-owned subsidiary of Aion TherapeuticToronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas... Read More...